Cédric Bisson

Chairman at

Procure

Health Technology

Consumer Services

Finance

Profile

Cédric Bisson is currently the Chairman at Procure and the Director at Iaculor Injection, Inc. He also holds the position of Director at Grand Challenges Canada, Northern Biologics, Inc., 35Pharma, Inc., and Associate at Teralys Capital, Inc. In the past, Dr. Bisson worked as a Director at Milestone Pharmaceuticals, Inc. and Mimetogen Pharmaceuticals, Inc. He was also the Managing Partner at iNovia Capital, Inc. from 2003 to 2010 and an Associate Principal at McKinsey & Co., Inc. (Canada).
Dr. Bisson holds a doctorate degree from McGill University and a graduate degree from the University of Montréal.

Cédric Bisson active positions

Companies	Position	Start
Teralys Capital, Inc. Teralys Capital, Inc. Investment ManagersFinance Teralys Capital is a technology-focused fund-of-funds that finances private venture capital funds. The firm focuses on funds that invest in information technology, the life sciences and clean technology companies. Their partner funds cover a range of opportunities including early-stage start-ups, expansion-stage, growth-stage and technology buyouts. They invest primarily in Quebec and Canada but also considers investments internationally. They make direct fund investments but they may also invest in a small percentage of secondary transactions. They partner with other private or international co-investors, either directly as investors in their own fund or as co-investors in their portfolio companies.	Private Equity Investor	2011-08-31
Procure	Chairman	-
Grand Challenges Canada Grand Challenges Canada Medical/Nursing ServicesHealth Services Provides support services for healthcare	Director/Board Member	2016-05-03
Iaculor Injection, Inc. Iaculor Injection, Inc. Medical SpecialtiesHealth Technology Develops needle free medical devices	Director/Board Member	-
Northern Biologics, Inc. Northern Biologics, Inc. Hospital/Nursing ManagementHealth Services Developing novel therapeutic antibodies for the treatment of human diseases in oncology and fibrosis	Director/Board Member	-
35Pharma, Inc. 35Pharma, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that engages in designing and developing of TGF-beta superfamily therapeutics	Director/Board Member	-

All active positions of Cédric Bisson

Former positions of Cédric Bisson

Companies	Position	End
MILESTONE PHARMACEUTICALS INC.	Director/Board Member	2012-03-04
iNovia Capital, Inc. iNovia Capital, Inc. Investment ManagersFinance iNovia Capital invests in companies located in Canada & the United States. The firm targets companies operating in the fields of commerce, digital health, enterprise platforms, future of work, Security and travel & hospitality sectors. It provides financing for seed and early stage capital requirements.	Private Equity Investor	2010-12-21
McKinsey & Co., Inc. (Canada) McKinsey & Co., Inc. (Canada) Miscellaneous Commercial ServicesCommercial Services Provides management consulting services	Corporate Officer/Principal	-
░░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░	░░░░░░░░░░░░░░ ░░░░░░	-

See the detail of Cédric Bisson's experience

Training of Cédric Bisson

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Cédric Bisson's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	12
Milestone Pharmaceuticals, Inc. Milestone Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures cardiovascular medicines	Health Technology
McGill University McGill University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
University of Montréal University of Montréal Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
iNovia Capital, Inc. iNovia Capital, Inc. Investment ManagersFinance iNovia Capital invests in companies located in Canada & the United States. The firm targets companies operating in the fields of commerce, digital health, enterprise platforms, future of work, Security and travel & hospitality sectors. It provides financing for seed and early stage capital requirements.	Finance
Iaculor Injection, Inc. Iaculor Injection, Inc. Medical SpecialtiesHealth Technology Develops needle free medical devices	Health Technology
Mimetogen Pharmaceuticals, Inc. Mimetogen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops peptidomimetic small molecule drugs against glaucoma and cancer	Health Technology
Procure
Teralys Capital, Inc. Teralys Capital, Inc. Investment ManagersFinance Teralys Capital is a technology-focused fund-of-funds that finances private venture capital funds. The firm focuses on funds that invest in information technology, the life sciences and clean technology companies. Their partner funds cover a range of opportunities including early-stage start-ups, expansion-stage, growth-stage and technology buyouts. They invest primarily in Quebec and Canada but also considers investments internationally. They make direct fund investments but they may also invest in a small percentage of secondary transactions. They partner with other private or international co-investors, either directly as investors in their own fund or as co-investors in their portfolio companies.	Finance
McKinsey & Co., Inc. (Canada) McKinsey & Co., Inc. (Canada) Miscellaneous Commercial ServicesCommercial Services Provides management consulting services	Commercial Services
Grand Challenges Canada Grand Challenges Canada Medical/Nursing ServicesHealth Services Provides support services for healthcare	Health Services
Northern Biologics, Inc. Northern Biologics, Inc. Hospital/Nursing ManagementHealth Services Developing novel therapeutic antibodies for the treatment of human diseases in oncology and fibrosis	Health Services
35Pharma, Inc. 35Pharma, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that engages in designing and developing of TGF-beta superfamily therapeutics	Health Technology